Last Updated: 2026

AbCellera

Rank#4963

Market Cap1.88B

CountryCanada

Summary

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

History

AbCellera was founded in 2012 by Carl Hansen and Ryan Cawood. Since then, the company has grown exponentially, with offices in Vancouver, Canada and San Francisco, CA. AbCellera has developed a platform for the discovery of therapeutic antibodies that is used by over 200 partners worldwide.

Mission

Our mission is to revolutionize the discovery of antibody-based drugs by harnessing the power of the human immune system.

Vision

Our vision is to build a more equitable and accessible healthcare industry by driving the development of novel therapies through our innovative technologies.

References

https://en.wikipedia.org/wiki/AbCellera

https://in.investing.com/equities/abcellera-biologics

https://finance.yahoo.com/quote/ABCL/profile?p=ABCL

https://www.crunchbase.com/organization/abcellera-biologics

https://sec.report/CIK/0001703057

https://companiesmarketcap.com/

https://www.abcellera.com

Leadership team

Dr. Carl L.G. Hansen Ph.D. (CEO, Pres & Chairperson)

Mr. Andrew Booth M.B.A. (Chief Financial Officer)

Dr. Veronique Lecault Ph.D. (COO & Director)

Products / Services

Biotechnology, Medical, Therapeutics

Number of Employees

100 - 500

Address

Vancouver, British Columbia, Canada

Established

2012-01-01

Company Registration

SEC CIK number: 0001703057

Net Income

S_100M_500M

Revenue

500M - 1B

Traded as

ABCL

Website

https://www.abcellera.com

Social Media

Last Updated: 2026

AbCellera

Rank#4963

Market Cap1.88B

CountryCanada

Summary

History

Mission

Our mission is to revolutionize the discovery of antibody-based drugs by harnessing the power of the human immune system.

Vision

Our vision is to build a more equitable and accessible healthcare industry by driving the development of novel therapies through our innovative technologies.

References

https://en.wikipedia.org/wiki/AbCellera

https://in.investing.com/equities/abcellera-biologics

https://finance.yahoo.com/quote/ABCL/profile?p=ABCL

https://www.crunchbase.com/organization/abcellera-biologics

https://sec.report/CIK/0001703057

https://companiesmarketcap.com/

https://www.abcellera.com

Leadership team

Dr. Carl L.G. Hansen Ph.D. (CEO, Pres & Chairperson)

Mr. Andrew Booth M.B.A. (Chief Financial Officer)

Dr. Veronique Lecault Ph.D. (COO & Director)